An observational study in End Stage Renal Disease, sponsored by Wenhu Liu. Completed at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-08-24.
Sponsored by Wenhu Liu · Observational
Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.
Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 6th largest by enrollment of the 31 observational ones, is one of 5 that started in 2012, is one of 31 observational ones, and was the 43rd registered.
2,108 studies on the registry are indexed under Kidney Failure, Chronic; 273 are open to participants now.
This study's enrollment of 1,000 is above the median of 120 across 442 observational studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →114 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 5 started in 2012.
Median enrollment 150 across the 83 interventional studies, 250 across the 31 observational. Of the 55 that completed or were terminated, 7 (13%) have results posted.
29 of 114 have an industry lead sponsor. The 10 most frequent:
Wenhu Liu is the lead sponsor of 4 studies on the registry; none are open to participants now.
Wenhu Liu has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Failure, Chronic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05639010Changhai HospitalEffects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study | 2026-12-31 |
| NCT07350837Tongji HospitalCAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants | 2026-12-31 |
| NCT07291154Yunfeng XiaImpact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy | 2026-12-31 |
| NCT05315141Xiangya Hospital of Central South UniversityMulticenter Cohort Study of AAV in Hunan of China | 2027-03-16 |
| NCT07303179The First People's Hospital of YunnanExercise Rehabilitation for Functional Impairment in Maintenance Hemodialysis Patients | 2027-06-01 |
Among the 114 studies in Kidney Failure, Chronic with a site in China, from their registry updates:
Incidence of End Stage Renal Disease (ESRD) amongst elderly patient group is continuously increasing with population aging progressing. Mineral and bone disorder (MBD) is a common complication caused by ESRD, it raises the incidence of cardiovascular disease (CVD) in hemodialysis patients, as well as mortality.
Joint effects of Kidney failure and aging on elderly hemodialysis patients make the contribution factors of CKD-MBD quite complex, and it also leads to differences in clinic manifestation between elderly hemodialysis patients and non-elderly hemodialysis patients. Since not much studies had been done for this specific subject, thus, research on elderly patients who is taking Maintenance hemodialysis is very necessary. This study is a retrospective research to identify optimized target value of Calcium and Phosphorus for elderly patients taking maintenance hemodialysis and hence provide guidance for clinical practices. The data for this study will be provided by Beijing Blood Purification Quality Control and Improvement Center. Clinical files and Calcium and Phosphorus metabolic indices will be collected amongst elderly patients who were elder than 65 years and was taking maintenance hemodialysis between Jan 1st, 2012 through Dec 31st, 2016. Relationship between Calcium level, Phosphorus level, iPTH index, all-cause mortality and CVD caused mortality will be analyzed to identify optimized range of target Calcium levels, Phosphorus level for hemodialysis treatment
the data for this study will be provided by Beijing Blood Purification Quality Control and Improvement Center. Clinical files and Calcium and Phosphorus metabolic indices will be collected amongst elderly patients who were elder than 65 years and was taking maintenance hemodialysis between Jan 1st, 2012 through Dec 31st, 2016.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All-cause mortality
all patients died in our observation period
Time frame: 5 years
CVD-related mortality
the cause of death was cardiovascular disease related
Time frame: 5 years
Ran from Jan 2012 to primary completion in Dec 2016, 59 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wenhu Liu